MPe Myeloma Patients Europe

EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE

Understanding the challenges around implementing PROMs for patients receiving novel immunotherapies in haematology

Dr. Eilidh Duncan
Head of Patient Research
Myeloma Patients Europe

Joyner K[1], Broekhuizen C[2], Kyriakou C[3], Nier S[4], Oehrlein E[5], Oerlemans S[2], Reese E[5], Morgan K[1]

1. Myeloma Patients Europe; 2. Netherlands Comprehensive Cancer Organisation (IKNL); 3. University College London Hospitals NHS Trust; 4. Acute Leukemia Advocates Network; 5. Applied Patient Experience

Financial Disclosures

MPE received financial support for this project from GlaxoSmithKline, Kite, a Gilead Company, Bristol Myers Squibb, Janssen and Regeneron.

Introduction

Haematological Malignancies

- Myeloma, Lymphoma, Leukaemia.
- **40-50%** patients relapse and/or develop refractory disease.
- Novel immunotherapies offer innovative treatments
  - **Chimeric Antigen Receptor T cell (CAR-T) therapy.**
  - **Bispecific Antibody treatments.**
- Promising results but potentially serious side-effects.
  - Cytokine Release Syndrome 87% CAR-T, 67% Bispecific antibody treatments
- Expensive medicines ➡ important to evaluate impact on patients in terms of safety, efficacy and patients' quality of life.

Symptoms of Myeloma



Patient Reported Outcome Measures (PROMs)

Capture patients' perspectives on their health, symptoms and quality of life

Commonly used PROMs in myeloma clinical trials (2011-2021)

- EORTC QLQ-C30
- PRO-CTCAE
- EORTC QLQ-MY20
- EQ-5D-3L
- EQ-5D-5L

Only 33% of global trials, and 41% of European trials intended to collect PRO data.

No current validated PROMs for use among people with haematological cancers receiving CAR-T and bispecific antibody treatments.

Myeloma Patients Europe (MPE): (2023). ***Assessment of quality of life data in myeloma clinical trials between 2011-2021.***

Understanding the challenges in PROM for Bispecific Antibody and CAR-T treatments in haematology

Project Aims

1. Understand current experiences, perspectives and challenges.

2. Explore what can be done now and in the future to improve our understanding of haematology patients' experiences of novel immunotherapies.

Methods

Online workshops x 2 March/April 2024 (n=30)
Online interviews x13 (n=15)



Workshop insights

Patients' experiences of side-effects

CAR-T

low blood pressure, difficulty concentrating, depression.

Fear and anxiety.

"I lost my sense of smell which I have not regained since."

CRS

Fatigue, fever, chills, sweating, loss of appetite, taste, loss of smell.

"There were multiple hospitalisations, I was often on steroids. It was a pretty miserable seven weeks."

Bispecific antibody treatments

"I couldn't open boxes when I was cooking… I always had to ask someone else just because your nails are so frail, that's very painful."

Dizziness, cough, loss of appetite and taste, skin and nails.

Immunocompromised state social and work impacts.

Workshop insights

Challenges of what PROMs to use

No single PROM captures all the domains important to patients treated with novel immunotherapies



Workshop insights

Challenges on when to collect PROMs

Timing of PROM collection

Baseline assessments

1st day in hospital or treatment day 1

And/or when treatment first offered

First follow-up

One week after infusion/initiation

Subsequent follow-up

First 2 months - weekly

Long-term follow-up

CAR-T: every 6 months then annual assessment of broader impact

Bispecific antibodies treatments: longer-term administration context



Patient burden and feasibility constraints

Workshop insights

Improving PROM data collection

Efficiency

- Integrating data capture into routine clinic visits
- Electronic capture of PROs, apps, websites or a ‘bring your own device’ but with paper as back-up

“Whole patient” perspective

- Capturing nuances of patients and carers’ experiences and broader impacts including emotional, social and mental health
- Interviews and open-ended responses

Specific tailored and validated PROM for novel immunotherapies

- Multi-stakeholder collaboration essential to develop and refine



Three key takeaways

PROMs for CAR-T and Bispecifics are currently inadequate



Tailored and timely PROMs are essential

Collaboration and technology can improve PROMs

THANK YOU!

To the participants of our workshops and interviews, and to our collaboration team






References

1. Bellino S, La Salvia A, Cometa MF, Botta R. Cell-based medicinal products approved in the European Union: current evidence and perspectives. Front Pharmacol. 2023 Jul 31;14:1200808. doi: 10.3389/fphar.2023.1200808. PMID: 37583902; PMCID: PMC10424920.
2. Sheena Sharma, Diane Wang, Hoi-Kei Lon, Pooneh Soltantabar, Andrea Viqueira, Akos Czibere, Anne Hickman, Jane Liang White, Mohamed Elmeliegy; A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma. Blood 2022; 140 (Supplement 1): 10036–10038. doi: https://doi.org/10.1182/blood-2022-169836
3. Azoulay É, Castro P, Maamar A, Metaxa V, de Moraes AG, Voigt L, Wallet F, Klouche K, Picard M, Moreau AS, Van De Louw A, Seguin A, Mokart D, Chawla S, Leroy J, Böll B, Issa N, Levy B, Hemelaar P, Fernandez S, Munshi L, Bauer P, Schellongowski P, Joannidis M, Moreno-Gonzalez G, Galstian G, Darmon M, Valade S; Nine-I investigators. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematol. 2021 May;8(5):e355-e364. doi: 10.1016/S2352-3026(21)00060-0. PMID: 33894170.
4. Myeloma Patients Europe (MPE). Assessment of quality of life data in myeloma clinical trials between 2011-2021. 2023. https://www.mpeurope.org/wp-content/uploads/2023/01/QoL-in-myeloma-report.pdf